Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News bioMerieux sees “sustained sales growth”

bioMerieux sees “sustained sales growth”

9th September 2008

In vitro diagnostics specialist bioMeriux recorded "sustained sales growth" during the first six months of 2008, alongside consolidated profitability and higher operating income in its latest financial report.

The company’s net sales for the first half of the year were 528.2 million euros (424.65 million pounds), up 1.9 per cent on the same period of 2007.

Gross profits, meanwhile, were clocked at 286.4 million euros, 4.8 per cent higher than the 273.3 million euros recorded in the first half of last year.

In addition, operating income was up 7.6 per cent year-on-year at 84 million euros, compared to the previous figure of 78.1 million euros.

During the period covered by the report, the company launched its Full Microbiology Lab Automation concept at the European Congress of Clinical Microbiology and Infectious Diseases, as well as the General Meeting of the American Society for Microbiology.

It also released 15 new reagents and two software applications, began marketing the Vidas NT-proBNP heart failure diagnostic test in the United States and completed the purchase of Swedish diagnostics firm AB Biodisk.

The company also recently confirmed Steve Harbin as its new corporate vice-president for quality management systems, internal control strategies and health, safety and environment.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.